Biotech Values

[DewDiligence]

ITEK -45%/AH on phase-2 failure:

https://www.businesswire.com/news/home/20170707005601/en

“While the top-line results, which we received and analyzed over the past week, demonstrated a good safety and tolerability profile of the fixed-dose combinations of trabodenoson and latanoprost, the efficacy of the FDC was only marginally differentiated from that of latanoprost alone. Based on these results and the results previously reported for our Phase 3 MATrX-1 monotherapy trial, we are evaluating the future clinical potential of trabodenoson, as well as other strategic options.”

CC Monday at 8:30am ET.